Poisoning - Tricyclic Antidepressant

This guideline is a general approach to tricyclic antidepressant poisoning. For specific details please contact **Poisons Information: 131126** or refer to the Toxicology Handbook.

**Agents:**

- Amitriptyline
- Clomipramine
- Dothiepin
- Doxepin
- Imipramine
- Nortriptyline
- Trimipramine

**Background**

Tricyclic antidepressants (TCAs) act on a variety of receptors whose actions include:

- Noradrenaline reuptake inhibition
- Central and peripheral anticholinergic effect
- Fast sodium channel blockade in the myocardium
- Peripheral alpha1-adrenergic receptor blockade

The life threatening effects of acute tricyclic antidepressant (TCA) overdose are:

- Rapid onset of coma
- Seizures
- Cardiac dysrhythmias
Hypotension and central and peripheral anticholinergic effects may also be seen

**Risk Assessment**

- Most acute accidental paediatric exposures do not result in life threatening toxicity
- A 10kg child can develop life threatening poisoning with the ingestion of a single tablet (e.g. 150mg amitriptyline)
- Patients who ingest a large dose of TCA usually develop evidence of intoxication within 2-4 hours, and always within 6 hours
- If there is suspicion of deliberate self poisoning patients are to be referred for evaluation in hospital, regardless of the dose ingested

**Typical Clinical Course**

Common effects following acute TCA ingestion include:

- Drowsiness
- Ataxia
- Sinus tachycardia
- Dilated pupils
- Decreased bowel sounds
- Ileus and Urinary retention

Life threatening effects following acute TCA overdose are:

- Coma
- Seizures
- Ventricular dysrhythmia
- Hypotension
- Central and Peripheral anticholinergic effects may also be seen

<table>
<thead>
<tr>
<th>Ingested Dose</th>
<th>Symptoms and Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 5 mg/kg</td>
<td>Minimal toxicity</td>
</tr>
<tr>
<td></td>
<td>Patients do not require decontamination or referral to hospital except in cases of deliberate overdose</td>
</tr>
<tr>
<td>5 - 10 mg/kg</td>
<td>Major symptoms unlikely</td>
</tr>
<tr>
<td></td>
<td>Mild anticholinergic effects may be present</td>
</tr>
<tr>
<td></td>
<td>• Drowsiness</td>
</tr>
<tr>
<td></td>
<td>• Tachycardia</td>
</tr>
<tr>
<td></td>
<td>Patients should be referred to hospital for evaluation and observation and may be discharged if asymptomatic at 6 hours post ingestion.</td>
</tr>
</tbody>
</table>
> 10mg/kg | **Life threatening effects:**  
|  | • Coma  
|  | • Seizures  
|  | • Cardiac dysrhythmias  
|  | • Hypotension  
|  | Anticholinergic effects are likely but often masked by coma  
|  | Patients are to be admitted to the PICU. Intubation and hyperventilation may be required.

> 30mg/kg | **Severe toxicity with pH-dependent cardiotoxicity and coma expected to at least >24 hours**  
|  | Patients are to be admitted to PICU. Intubation and hyperventilation may be required.

### Investigations

**Screening (for deliberate overdose):**

- BSL  
- Paracetamol level (if deliberate ingestion)

### Specific

- Serial 12 lead ECG
  - Prolonged QRS interval (sodium channel blockade)  
    - > 100ms predicts risk of seizures  
    - > 160ms predicts risk of ventricular tachycardia  
  - Large terminal R wave in aVR  
  - Increased R/S ratio (> 0.7) in aVR  
  - Prolonged QT interval (potassium channel blockade)

- Blood gas (pH)

### Management

**Resuscitation**

Overdose may be life-threatening and should be managed in a resuscitation bay with cardiac monitoring. Cardiac monitoring should continue for at least 6 hours post-ingestion or until resolution of toxicity.

**Potential early life-threats that require immediate intervention include:**

- Coma  
- Respiratory compromise  
- Seizures  
- Cardiac dysrhythmia  
- Cardiac arrest
Life-threatening overdose will require intubation and hyperventilation to a pH of 7.50-7.55. Bicarbonate boluses may be required just prior to intubation to optimise cardiovascular status.

**Reduced level of consciousness**

- Intubation and hyperventilation are indicated if the GCS falls below 12

**Ventricular dysrhythmias**

- Sodium bicarbonate boluses (100mmol or 2mmol/kg) IV every 1-2 minutes is given until restoration of the perfusing rhythm and normalisation of the QRS.
- Cardioversion and defibrillation are unlikely to be effective.
- Type Ia antidysrhythmic agents (e.g. procainamide), amiodarone and beta-blockers are **contraindicated**.
- Serial ECGs should be performed every 5-10 minutes until ECG abnormalities are stabilised.

**Hypotension**

- Treat with IV crystalloid solutions (10–20 mL/ kg) and assess response
- Refractory hypotension may require sodium bicarbonate and adrenaline or noradrenaline infusion

**Seizures**

- Benzodiazepines are first-line treatment
- Phenytoin is **contraindicated**

**Decontamination**

Activated charcoal 1gram/kg indicated for ingestions > 10mg/kg but should not be given until the airway is secured by ETT and after dealing with resuscitation requirements.

**Enhanced Elimination**

No role

**Antidote**

Sodium bicarbonate, as above

**Disposition**

- Any patient who is asymptomatic at 6 hours can be medically cleared.
Patients who have mild ECG or mental state changes should be admitted to a medical ward and require ongoing careful observation and regular ECGs. Patients with significant TCA overdose will require PICU admission.

Nursing

- Baseline observations: heart rate, respiratory rate, oxygen saturation, blood pressure, and neurological observations
- Minimum of hourly observations should be recorded whilst in the emergency department
- Any significant changes should be reported immediately to the medical team
- Baseline ECG on arrival and as required throughout presentation
- Continual cardiac monitoring
- Blood sugar level for patients with reduced level of consciousness
- Ensure the patient is always aided when ambulating to prevent a fall
- Fluid balance (urinary retention is a common anticholinergic effect)

References

2. Poisons Information Service 131126

This document can be made available in alternative formats on request for a person with a disability.
<table>
<thead>
<tr>
<th>Endorsed by:</th>
<th>Medical Advisory Committee</th>
<th>Date:</th>
<th>30 September, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standards Applicable:</td>
<td>NSQHS Standards: ☣ ☣ ☣</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Printed or personally saved electronic copies of this document are considered uncontrolled**